World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
88
Citations
26050
World Ranking
13248
National Ranking
6748

David G. McLeod publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where David G. McLeod sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 505 publications — 59th percentile

59% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

David G. McLeod D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where David G. McLeod sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 88 D-Index — 36th percentile

36% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

David G. McLeod was affiliated with the Uniformed Services University of the Health Sciences in the United States. Their research primarily focused on medical and biomedical fields, particularly within medicine, engineering, and biochemistry, genetics, and molecular biology.

The subfields of McLeod's work included pulmonary and respiratory medicine, biomedical engineering, molecular biology, cardiology and cardiovascular medicine, and cancer research.

Main research topics addressed through their work were:

  • Prostate cancer treatment and research
  • Prostate cancer diagnosis and treatment
  • Microfluidic and capillary electrophoresis applications
  • Innovative microfluidic and catalytic techniques innovation
  • Cardiac electrophysiology and arrhythmias
  • 3D printing in biomedical research
  • Cancer, lipids, and metabolism

Some of their frequent coauthors included Shiv Srivastava, Zhenyu Li, Albert Dobi, Inger L. Rosner, and Isabell A. Sesterhenn, with collaboration counts ranging from six to nine works.

David G. McLeod published multiple research articles in various scientific journals, notably in bioRxiv (Cold Spring Harbor Laboratory), Scientific Reports, Cancer Epidemiology Biomarkers & Prevention, Cancer, and Prostate Cancer and Prostatic Diseases.

Notable papers authored or coauthored by McLeod included:

  • "Survival of African-American and Caucasian men after sipuleucel-T immunotherapy: outcomes from the PROCEED registry," 2020, published in Prostate Cancer and Prostatic Diseases
  • "Multi-omic serum biomarkers for prognosis of disease progression in prostate cancer," 2020, published in Journal of Translational Medicine
  • "Prognostic features of Annexin A2 expression in prostate cancer," 2020, published in Pathology
  • "Focal p53 protein expression and lymphovascular invasion in primary prostate tumors predict metastatic progression," 2022, published in Scientific Reports
  • "Clinical utility of a serum biomarker panel in distinguishing prostate cancer from benign prostate hyperplasia," 2021, published in Scientific Reports

Best Publications

  • A controlled trial of leuprolide with and without flutamide in prostatic carcinoma.

    E D Crawford;M A Eisenberger;D G McLeod;J T Spaulding

  • Bilateral orchiectomy with or without flutamide for metastatic prostate cancer

    Mario A. Eisenberger;Brent A. Blumenstein;E. David Crawford;Gary Miller

  • Age-Specific Reference Ranges for Serum Prostate-Specific Antigen in Black Men

    Ted O. Morgan;Steven J. Jacobsen;William F. McCarthy;Debra J. Jacobson

  • Frequent Detection of Codon 877 Mutation in the Androgen Receptor Gene in Advanced Prostate Cancers

    Jaya P. Gaddipati;David G. McLeod;Howard B. Heidenberg;Isabell A. Sesterhenn

  • Identification of Putative Stem Cell Markers, CD133 and CXCR4, in hTERT–Immortalized Primary Nonmalignant and Malignant Tumor-Derived Human Prostate Epithelial Cell Lines and in Prostate Cancer Specimens

    Jun Miki;Bungo Furusato;Hongzhen Li;Yongpeng Gu

  • Pathologic Variables and Recurrence Rates As Related to Obesity and Race in Men With Prostate Cancer Undergoing Radical Prostatectomy

    Christopher L. Amling;Robert H. Riffenburgh;Leon Sun;Judd W. Moul

  • Frequent overexpression of ETS-related gene-1 (ERG1) in prostate cancer transcriptome

    Gyorgy Petrovics;Aijun Liu;Syed Shaheduzzaman;Bungo Furasato

  • NEOADJUVANT ANDROGEN ABLATION BEFORE RADICAL PROSTATECTOMY IN cT2bNxMo PROSTATE CANCER: 5-YEAR RESULTS

    Mark S. Soloway;Kapil Pareek;Rooholiah Sharifi;Zev Wajsman

  • PCGEM1, a prostate-specific gene, is overexpressed in prostate cancer

    Vasantha Srikantan;Zhiqiang Zou;Gyorgy Petrovics;Linda Xu

  • Bicalutamide 150 mg plus standard care vs standard care alone for early prostate cancer.

    David G. Mcleod;Peter Iversen;William A. See;Thomas Morris

  • Pretreatment Total Testosterone Level Predicts Pathological Stage in Patients With Localized Prostate Cancer Treated With Radical Prostatectomy

    Jason C. Massengill;Leon Sun;Judd W. Moul;Hongyu Wu

  • Prostate-Specific Antigen Values at the Time of Prostate Cancer Diagnosis in African-American Men

    Judd W. Moul;Isabell A. Sesterhenn;Roger R. Connelly;Thomas Douglas

  • Early versus delayed hormonal therapy for prostate specific antigen only recurrence of prostate cancer after radical prostatectomy.

    Judd W. Moul;Judd W. Moul;Hongyu Wu;Leon Sun;David G. McLEOD

  • Elevated Levels of Apoptosis Regulator Proteins P53 and BCL-2 are Independent Prognostic Biomarkers in Surgically Treated Clinically Localized Prostate Cancer

    John J. Bauer;Isabell A. Sesterhenn;F.K. Mostofi;David G. McLeod

  • Bicalutamide as immediate therapy either alone or as adjuvant to standard care of patients with localized or locally advanced prostate cancer: first analysis of the early prostate cancer program

    William A. See;Manfred P. Wirth;David G. McLeod;Peter Iversen

  • TMPRSS2-ERG fusion, a common genomic alteration in prostate cancer activates C-MYC and abrogates prostate epithelial differentiation.

    C. Sun;A. Dobi;A. Mohamed;H. Li

  • MULTICENTER PATIENT SELF-REPORTING QUESTIONNAIRE ON IMPOTENCE, INCONTINENCE AND STRICTURE AFTER RADICAL PROSTATECTOMY

    Tzu-Cheg Kao;David F. Cruess;Daniel Garner;John Foley

  • BICALUTAMIDE 150 MG IN ADDITION TO STANDARD CARE IN PATIENTS WITH LOCALIZED OR LOCALLY ADVANCED PROSTATE CANCER: RESULTS FROM THE SECOND ANALYSIS OF THE EARLY PROSTATE CANCER PROGRAM AT MEDIAN FOLLOWUP OF 5.4 YEARS

    Manfred P. Wirth;William A. See;David G. McLEOD;Peter Iversen

  • ERG oncoprotein expression in prostate cancer: clonal progression of ERG-positive tumor cells and potential for ERG-based stratification

    Furusato B;Tan Sh;Young D;Dobi A

  • PSGR, a novel prostate-specific gene with homology to a G protein-coupled receptor, is overexpressed in prostate cancer.

    Linda L. Xu;Bennett G. Stackhouse;Kim Florence;Wei Zhang

Frequent Co-Authors

Shiv Srivastava
Shiv Srivastava Uniformed Services University of the Health Sciences
Judd W. Moul
Judd W. Moul Duke University
Isabell A. Sesterhenn
Isabell A. Sesterhenn United States Army Research Laboratory
Anthony V. D'Amico
Anthony V. D'Amico Brigham and Women's Hospital
Peter R. Carroll
Peter R. Carroll University of California, San Francisco
Mario A. Eisenberger
Mario A. Eisenberger Johns Hopkins University
Oliver Sartor
Oliver Sartor Tulane University
E. David Crawford
E. David Crawford University of California, San Diego
Philip W. Kantoff
Philip W. Kantoff Memorial Sloan Kettering Cancer Center
Matthew L. Freedman
Matthew L. Freedman Harvard University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring alternative online medical and healthcare degrees can open new doors for those interested in medicine but seeking different paths. For instance, direct msn programs online are a fast-track option for non-nurses looking to advance quickly in the nursing profession. These programs allow individuals with a non-nursing background to obtain a Master of Science in Nursing through an accelerated, flexible format.

Prospective nursing students concerned about admission barriers might consider researching what is the easiest nursing school to get into. This list highlights schools with less competitive entry requirements, making the transition into nursing more accessible.

Beyond clinical practice, allied health degrees like medical billing and coding schools that accept financial aid provide entry into essential behind-the-scenes roles. These accredited programs offer important financial support options for students.

Finally, if standardized tests are a concern, you may want to apply to nursing schools that don't require teas or HESI exams. These schools focus on alternative admission criteria, potentially simplifying your journey toward a nursing career.

Best Scientists Citing David G. McLeod

Recently Published Articles